Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 16/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15012028 | 1.00 | TRPA1 (0.57) | TRPA1ARCNR2SLC22A12TAS2R14 | |
| SCHEMBL15012027 | 1.00 | TRPA1 (0.57) | TRPA1ARCNR2SLC22A12TAS2R14 | |
| SCHEMBL16216532 | 0.99 | TRPA1 (0.56) | TRPA1ARCNR2SLC22A12TAS2R14 | |
| SCHEMBL16219513 | 0.99 | TRPA1 (0.56) | TRPA1ARCNR2SLC22A12TAS2R14 | |
| SCHEMBL15970604 | 0.81 | FER (0.41) | TRPA1 | |
| SCHEMBL20274107 | 0.81 | TRPA1 (0.61) | TRPA1ARCNR2 | |
| SCHEMBL29666012 | 0.79 | TRPA1 (0.53) | TRPA1ARCNR2SLC22A12TAS2R14 | |
| SCHEMBL15014051 | 0.79 | TRPA1 (0.48) | TRPA1ARCNR2SLC22A12TAS2R14 | |
| SCHEMBL15014053 | 0.79 | TRPA1 (0.48) | TRPA1ARCNR2SLC22A12TAS2R14 | |
| SCHEMBL15014050 | 0.79 | TRPA1 (0.48) | TRPA1ARCNR2SLC22A12TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | AR, UTS2R, FSHR | TRPA1 2395/4885AR 1/4885CNR2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.